Menopause After Breast Cancer: What You Can Do

Leaving women to struggle through treatment-induced menopause without offering help is its own kind of harm.

The last treatment is done. Everyone around her is relieved, and she’s supposed to finally “feel like herself again.” Instead, she’s waking up drenched multiple times per night, running on five hours of broken sleep, experiencing brain fog, extreme fatigue, low moods, anxiety, and has no interest in intimacy. When she brings this up at her next appointment, the response, spoken or not, is some version of: You’re alive. Be grateful.

She is grateful. But gratitude and quality of life are not the same thing. Surviving cancer and wanting to feel well in your own body are not competing goals, and no one should be asked to choose between them.

More than four million breast cancer survivors live in the United States today, and roughly one in five is diagnosed before age 50 (National Breast Cancer Foundation; Young Survival Coalition). For many of these women, menopause doesn’t arrive gradually and, even worse, without warning or proactive management. In a survey by the organization Menopause and Cancer, 88% of breast cancer survivors reported inadequate menopause support. To be honest, I’m surprised the percentage wasn’t higher.

While menopause management is a crucial component of cancer survivorship care, it is often completely neglected, leaving survivors struggling and wondering where they can go for evidence-based support. Here’s what you should know and what you can do.

Often, yes. Here are ways that treatment can induce menopause for breast cancer survivors:

Chemotherapy is lifesaving but also toxic. The ovaries are sensitive organs, and chemotherapy can damage the ovaries and cause a decline in ovarian function, leading to a loss of periods, hormones, and menopause. For some women, periods return and chemotherapy-induced menopause is temporary; for others, especially those closer to natural menopause age, the change is permanent.

Endocrine therapy and ovarian suppression (tamoxifen, aromatase inhibitors, or medications that shut down the ovaries like Lupron) lower or block estrogen. These medications induce menopause and are known to cause significant menopausal symptoms.

Surgery to remove the ovaries, often recommended for women with a BRCA mutation and those with estrogen-sensitive cancers, causes immediate menopause. I always explain this like a “shock to the system” as the body goes into menopause in an instant.

Treatment-induced menopause causes an abrupt, exquisite decline in estrogen and other hormones produced by the ovaries, including progesterone and, to a lesser degree, testosterone. It is well established that women who experience premature and early induced menopause from cancer treatments suffer from more severe menopausal symptoms than those who enter menopause naturally, a process that can take up to 10 years.²

In a large community-based survey, 90% of survivors struggled with hot flashes, night sweats, or sleep disturbance; 75% with vaginal dryness; 62% with mood changes; and 60% with sexual dysfunction. Only 32% were offered any treatment.⁵ The most common symptoms include:

• Hot flashes and night sweats, often amplified by endocrine therapy.
• Sleep, mood, and cognitive changes, such as insomnia, irritability, anxiety, fear of recurrence, and brain fog.
• Genitourinary syndrome of menopause (GSM): vaginal dryness, painful intimacy, urinary urgency, and recurrent UTIs.
• Bone loss and joint aches, especially common with aromatase inhibitors.

These aren’t minor inconveniences. GSM can become severe enough that some women stop taking their life-saving endocrine therapy, and early menopause carries long-term risks for bone, heart, and brain health.

One of the most pressing and controversial questions is whether systemic hormone therapy (MHT) can be safely considered in breast cancer survivors. When we talk about systemic MHT, we mean hormones that travel throughout the entire body and brain in the form of a patch, gel, spray, oral pills, vaginal ring, or injections. This is very different from local, vaginal estrogen, which is discussed below.

Historically, a history of breast cancer was a firm contraindication to MHT. However, recent publications have begun to challenge this blanket approach, acknowledging that not all breast cancers, or patients, are the same and should not be treated as such. For example, triple-negative breast cancer, which is not a hormonally driven cancer and does not require treatment-induced menopause, is not considered a contraindication to MHT. Many of these patients will go on to have regular periods and make their own hormones for many years following their cancer treatments without impacting cancer recurrence or survival. This is a very different situation from a breast cancer survivor with estrogen-positive disease whose treatment relies on reducing estrogen levels in treating the cancer and preventing it from coming back.

In the Menopause Society Practice Pearl entitled Considerations for Hormone Therapy Use in Survivors of Breast Cancer, published in May 2025, Dr. Holly Pederson writes, “Lifestyle changes and nonhormone interventions remain the primary approach to managing estrogen-deficiency symptoms in this population. However, if the patient’s symptoms remain bothersome, with a significant effect on quality of life despite nonhormone therapy, systemic HT may be considered.”⁷

In Hormone Replacement Therapy After Breast Cancer: It Is Time, oncologist Dr. Avrum Bluming, co-author of Estrogen Matters, reviews 25 studies on this topic.⁴ Only one, the HABITS trial, showed an increased risk of recurrence, but none, including HABITS, demonstrated increased mortality from systemic hormone use. Additionally, it should be noted that HABITS required no baseline breast imaging, such as mammography, prior to entry into the trial, a significant limitation of this study. This nuanced evidence suggests that systemic hormone therapy may be appropriate in select cases, and that risk must be individualized rather than generalized.

You deserve a seat at the table when decisions about your body are being made.

While official guidelines for systemic HT in breast cancer survivors are still lacking, the use of low-dose vaginal estrogen to treat the genitourinary syndrome of menopause (GSM) is broadly endorsed. Professional organizations including the Menopause Society, American Urological Association, and ACOG agree: low-dose vaginal estrogen is safe for all breast cancer survivors, including those on endocrine therapy. GSM, a condition caused by estrogen deficiency in the vulva, vagina, and urinary tract, includes symptoms such as vaginal dryness, painful intercourse, urinary urgency, incontinence, recurrent UTIs, and pelvic floor dysfunction. Left untreated, GSM can lead to a complete inability to engage in sex, relationship issues, mental health decline, poor body image, and in extreme cases, even death from urosepsis.

Symptoms of GSM can be so severe that patients can become non-adherent to their life-saving endocrine therapies. Not only is low-dose vaginal estrogen a safe and effective treatment for this condition, but a powerful database study presented at the ASCO 2025 meeting demonstrated an increase in overall survival as well as breast cancer survival among breast cancer survivors who used vaginal estrogen for more than seven years.⁸ The fact that less than half of breast cancer survivors are being offered this treatment highlights the urgent need for education among oncology clinicians as well as a cultural shift in how menopause and sexual dysfunction are addressed in survivorship.

There are many effective non-hormonal options to manage menopausal symptoms.

• Lifestyle is key: keep the bedroom no warmer than 68 degrees at night, limit alcohol, engage in daily movement and anti-inflammatory nutrition, and track your personal triggers, including stress.
• Cognitive behavioral therapy (CBT) has evidence for reducing the severity of these symptoms.
• Non-hormonal prescriptions include certain antidepressants, gabapentin, and the newer neurokinin-3 (NK3) receptor antagonists, which act directly on the brain’s temperature-control center. One of these, elinzanetant, has been studied specifically in women on endocrine therapy for breast cancer, though long-term data is lacking.
• Your clinician can weigh which option seems like the best fit since some antidepressants (such as paroxetine and fluoxetine) can interfere with tamoxifen.
• If you’re exploring over-the-counter support either as a stand-alone option or in conjunction with a prescription medication, Solv Wellness Hot Flash Relief is worth considering.

• Non-hormonal vaginal moisturizers and lubricants (which should be used during every intimate encounter) are essential. It’s important to know that non-hormonal moisturizers often need to be used more often than vaginal estrogen, at least 3-5 times per week.
• Products like Via® are designed for vaginal dryness and made with science-backed ingredients including hyaluronic acid, jojoba oil, vitamins C and E, CoQ10, and peptides.
• Pelvic floor physical therapy and vaginal dilators can also help with pain, especially if there’s tightening at the entrance to the vagina and/or pelvic floor dysfunction.

• Daily movement is critical as movement lubricates joints and supports skeletal and muscle health.
• Adequate calcium and vitamin D, and regular bone density monitoring are essential, particularly on an aromatase inhibitor.
• Some women also look to supplements such as Solv Wellness Joint Support for achy joints. This product contains curcumin, which is known to reduce inflammation and reduce joint aches.

• As tissue and activity levels change, the urinary tract becomes more vulnerable.
• Stay hydrated, learn the early signs of a UTI, and speak up about recurrent infections.
• Tools like GennaMD can support UTI management.

Symptom management is a fundamental part of survivorship, not a luxury or an afterthought. Quality of life, health span, and longevity are core tenets of survivorship care, and menopause touches all three.

The first principle of medicine is “do no harm.” Leaving women to struggle through treatment-induced menopause without offering help is its own kind of harm. Survivors deserve the same menopause support as anyone else, regardless of the decision to use hormone therapy. Remember that local, low-dose vaginal estrogen is safe for all breast cancer survivors and that many non-hormonal approaches exist to combat many menopausal symptoms and support long-term health.

While menopause care is still not a standard component of survivorship care, many experts in this area, including myself, are driving the conversation forward, fostering a paradigm shift toward a modern, patient-centered approach to survivorship. While cancer survivors face many uncertainties, one thing is clear: every cancer survivor deserves individualized menopause care that prioritizes informed consent, shared decision-making, and patient autonomy.

1. Williams, N. O., et al. (2019). Time for action: Managing genitourinary syndrome of menopause. Journal of Oncology Practice, 15, 371–372.
2. Del Carmen, M. G., & Rice, L. W. (2017). Management of menopausal symptoms in women with gynecologic cancers. Gynecologic Oncology, 146(2), 427–435.
3. The North American Menopause Society. (2014). The menopause guidebook (10th ed.). The North American Menopause Society.
4. Bluming, A. Z. (2022). Hormone replacement therapy after breast cancer: It is time. The Cancer Journal, 28(3), 183–190.
5. Peate, M., Saunders, C., Cohen, P., & Hickey, M. (2021). Who is managing menopausal symptoms, sexual problems, mood and sleep disturbance after breast cancer and is it working? Findings from a large community-based survey of breast cancer survivors. Breast Cancer Research and Treatment, 187(2), 427–435.
6. Faubion, S. S., & Shufelt, C. (2022). The menopause management vacuum. The Cancer Journal, 28(3), 191–195.
7. Pederson, H. (2025). Considerations for hormone therapy use in survivors of breast cancer [Practice pearl]. The Menopause Society.
8. Mitchell, O., et al. (2025). Use of local estrogen therapy among breast cancer patients in SEER-MHOS database. Journal of Clinical Oncology, 43(Suppl.), Abstract 578.